伊马替尼治疗失败慢性期CML患者及早干预的意义及二代TKIs选择  

Impact of early intervention on chronic CML patients with imatinib failure and the selection of second-generation TKIs

作　　者：周励[1] 

机构地区：[1]上海交通大学医学院附属瑞金医院血液科,上海200025

出　　处：《中国新药杂志》2011年第17期1652-1656,共5页Chinese Journal of New Drugs

摘　　要：慢性髓细胞性白血病(CML)应用伊马替尼后,明显改善了预后,但治疗失败的患者则预后不良。为改善这些患者的预后,一方面需要加强细胞遗传学和分子生物学监测,及早发现治疗失败并给予干预。另一方面,对于大多数治疗失败的患者,二代酪氨酸激酶抑制剂(TKIs)是合适的选择,如果就目前临床上两种二代TKIs进行比较,总体看来尼洛替尼好于达沙替尼。lmatinib has been found to substantially improve outcomes in patients with chronic myeloid leukemia （CML）. However, imatinib use is complicated by development of resistance or intolerance resulting in imatinib failure, which indicates worse prognosis. Close cytogenetic and molecular monitoring can detect imatinib failure as soon as possible, and intervention is necessary if failure observed. For most of patients with imatinib failure, second-generation TKIs （nilotinb or dasatinib） are effective and well-tolerated options. Comparation between nilotinib and dasatinib, nilotinib seems the better choice.

关 键 词：慢性髓细胞白血病 伊马替尼治疗失败 达沙替尼 尼洛替尼 

分 类 号：R973[医药卫生—药品]